Financial Data and Key Metrics Changes - OPKO Health reported total revenues for Q4 2025 of $148.5 million, a decrease from $183.6 million in Q4 2024, primarily due to the Labcorp transaction [28] - The net loss for Q4 2025 was $31.3 million, or $0.04 per share, compared to a net income of $14 million, or $0.01 per diluted share in Q4 2024 [29] - The company ended the quarter with $369 million in cash and cash equivalents, which is sufficient to fund ongoing operations and development plans [21] Business Line Data and Key Metrics Changes - Revenue from the diagnostics business in Q4 2025 was $71.1 million, including $7 million from the 4Kscore test, which grew by over 16% compared to $6 million in Q4 2024 [22] - Revenue from the pharmaceutical segment was $77.4 million in Q4 2025, compared to $80.5 million in the prior year, with product sales increasing to $43.7 million from $37.4 million [24] - The operating loss for the diagnostics segment was $18.3 million, an improvement from $21.7 million in Q4 2024 [24] Market Data and Key Metrics Changes - Global pharmaceutical product sales grew by 17% year-over-year in 2025 [18] - The 4Kscore test volume increased by more than 6% year-over-year, with expectations for continued growth as payer coverage expands [19] Company Strategy and Development Direction - OPKO aims to position its diagnostics business for profitability, advance its ModeX pipeline, and strengthen its balance sheet through strategic partnerships and asset sales [4] - The company has streamlined its operations by divesting its oncology assets, allowing a focus on core clinical laboratory services and the 4Kscore test [5] - ModeX is a central component of OPKO's long-term strategy, with multiple clinical-stage programs and collaborations with Merck and Regeneron [6][12] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's momentum heading into 2026, with expectations for modest revenue growth and improving margins [5] - The company anticipates total revenue for Q1 2026 to be between $125 million and $140 million, reflecting weather impacts on volumes [29] - For the full year 2026, OPKO expects total revenue of $530 million to $560 million, with a focus on expanding R&D investments [31] Other Important Information - OPKO repurchased over $90 million in common shares and convertible notes in 2025, demonstrating a commitment to returning capital to shareholders [7] - The company received $28.5 million in non-dilutive funding from BARDA for its infectious disease programs [15] Q&A Session Summary Question: Timing of potential data disclosure for MDX-2001 - Management indicated that results from the Phase 1a trial will be shared by the end of 2026, with plans to enter Phase 1b for promising tumor types [38] Question: Drivers of NGENLA profit share increase - The increase was attributed to Pfizer's growth and market share gains, with expectations for continued growth in 2026 [40] Question: Growth in the 4K diagnostic test segment - Growth was primarily driven by urology field efforts, with expectations for continued upward momentum as payer coverage improves [45] Question: Studies for the EBV vaccine partnership with Merck - Ongoing studies aim to gather data on EBV naive patients, with Phase 2 expected to start next year [51] Question: Status of the GLP-1 glucagon combo asset - The asset is in the final stages of IND submission, with plans to enter Phase 1 once cleared [58]